Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $72 | $26 | $28 | $25 |
| % Growth | 176.2% | -7.7% | 12.6% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $4 |
| Gross Profit | $72 | $25 | $27 | $21 |
| % Margin | 100% | 94.8% | 95.1% | 83.3% |
| R&D Expenses | $42 | $44 | $42 | $42 |
| G&A Expenses | $10 | $12 | $10 | $9 |
| SG&A Expenses | $10 | $12 | $10 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52 | $56 | $51 | $51 |
| Operating Income | $20 | -$32 | -$25 | -$26 |
| % Margin | 27.5% | -122.3% | -87.3% | -103.7% |
| Other Income/Exp. Net | $1 | $0 | $0 | $1 |
| Pre-Tax Income | $20 | -$31 | -$24 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $20 | -$31 | -$24 | -$24 |
| % Margin | 28.2% | -120.8% | -86.3% | -96% |
| EPS | 0.21 | -0.32 | -0.25 | -0.27 |
| % Growth | 165.6% | -28% | 7.4% | – |
| EPS Diluted | 0.21 | -0.32 | -0.25 | -0.27 |
| Weighted Avg Shares Out | 97 | 97 | 96 | 90 |
| Weighted Avg Shares Out Dil | 98 | 97 | 96 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $24 | -$28 | -$21 | -$22 |
| % Margin | 33.3% | -106.9% | -73.3% | -86.6% |